Late last week, shares of CytoKinetics tanked when it put out the word that its lead drug for Lou Gehrig’s disease had missed the primary endpoint. Today, the biotech added that the ALS drug also missed a string of secondary endpoints, as well. There was, though, one bright spot: The drug achieved the secondary endpoint on what’s called “slow vital capacity,” billed as an important indication of disease prevention.

…read more

Source: CytoKinetics’ ALS drug also misses string of secondary endpoints


0 No comments